Asset Details
Do you wish to reserve the book?
O-GlcNAcylated FTO promotes m6A modification of SOX4 to enhance MDS/AML cell proliferation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
O-GlcNAcylated FTO promotes m6A modification of SOX4 to enhance MDS/AML cell proliferation
Do you wish to request the book?
O-GlcNAcylated FTO promotes m6A modification of SOX4 to enhance MDS/AML cell proliferation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
O-GlcNAcylated FTO promotes m6A modification of SOX4 to enhance MDS/AML cell proliferation
2025
Overview
Fat mass and obesity-associated protein (FTO) was the first m6A demethylase identified, which is responsible for eliminating m6A modifications in target RNAs. While it is well-established that numerous cytosolic and nuclear proteins undergo O-GlcNAcylation, the possibility of FTO being O-GlcNAcylated and its functional implications remain unclear. This study found that a negative correlation between FTO expression and O-GlcNAcylation in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The decreased O-GlcNAcylation on FTO can result in diminished m6A modification of SRY-related high mobility group box 4 (SOX4). This led to the promotion of cell apoptosis and inhibition of cell proliferation in MDS/AML. The O-GlcNAcylation of FTO stabilized SOX4 transcripts in an m6A-dependent manner, resulting in increased AKT and MAPK phosphorylation and decreased cell apoptosis. Inhibiting FTO O-GlcNAcylation significantly slowed AML progression in vitro, a finding supported by clinical data in MDS/AML patients. In conclusion, our study highlights the crucial role of FTO O-GlcNAcylation in RNA m6A methylation and the progression of MDS/AML, thereby providing a potential therapeutic avenue for these formidable diseases.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Acute myeloid leukemia (AML)
/ Adenosine - analogs & derivatives
/ Alpha-Ketoglutarate-Dependent Dioxygenase FTO - metabolism
/ Biomedical and Life Sciences
/ Body fat
/ Cancer
/ Cytokines and Growth Factors
/ Fat mass and obesity-associated protein (FTO)
/ Female
/ Humans
/ Leukemia
/ Leukemia, Myeloid, Acute - genetics
/ Leukemia, Myeloid, Acute - metabolism
/ Leukemia, Myeloid, Acute - pathology
/ Male
/ Myelodysplastic syndromes (MDS)
/ Myelodysplastic Syndromes - genetics
/ Myelodysplastic Syndromes - metabolism
/ Myelodysplastic Syndromes - pathology
/ O-linked N-acetyglucosamine (O-GlcNAc)
/ Post-translational modification
/ Proteins
/ SOXC Transcription Factors - genetics
/ SOXC Transcription Factors - metabolism
